Mela Sciences Cites Binding Study Protocol Pact As Key To FDA Reversal On MelaFind PMA
This article was originally published in The Gray Sheet
A rare binding study protocol agreement with FDA was a crucial factor in Mela Sciences’ successful campaign to reverse an initial “not approvable” determination for the firm’s melanoma detection device, according to CEO Joseph Gulfo.
You may also be interested in...
In an interview, Joseph Gulfo, former medtech industry CEO and vocal FDA critic, outlines his worldview and interest in pushing aggressively against increasing the FDA ‘body of law.’
Joseph Gulfo, a former medtech industry CEO and vocal FDA critic, is the latest candidate apparently being considered for FDA commissioner. In an interview with Medtech Insight, he outlines his worldview and interest in pushing aggressively against increasing the FDA "body of law."
The company's response to an FDA not-approvable letter for its LuViva cervical cancer scanner will be guided by the experiences of other light-based cancer detector developers that encountered the same initial setback. The firm's likely next step: petitioning FDA for an advisory panel meeting.